title: Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.
abstract: The diagnosis and treatment of erectile dysfunction has changed dramatically since the availability of safe and effective oral therapies. Unfortunately, not all men can be adequately treated in this way, and might require more invasive testing to diagnose and treat the specific cause of their dysfunction. This review looks at the tests and strategies available for men who cannot be treated by oral therapy alone.
authors.affiliation: Department of Urology, University of Texas Health Science Center and MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Jacobsohn
authors.forename: Run
authors.initials: R
authors.lastname: Wang
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D000792:Angiography; D001783:Blood Flow Velocity; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D010413:Penis / Q000098:blood supply / Q000000981:diagnostic imaging; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D004791:Enzyme Inhibitors; D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human